4DMedical (4DX) Life Sciences Virtual Investor Forum summary

Company overview and recent developments

• Specializes in cardiothoracic imaging with operations across three continents and recent expansion into Europe.

• Holds nine FDA approvals and is listed on the S&P/ASX 200 index.

• Recent acquisition in Europe strengthens presence and supports SaaS revenue growth.

Product innovation and market impact

• CT:VQ, the third-generation flagship product, enables functional lung imaging using existing CT infrastructure, eliminating the need for new hardware.

• Replaces traditional nuclear VQ scans, providing 3D, high-resolution images without radioactive agents or contrast injections.

• Offers significant workflow improvements, faster diagnosis, and better patient experience.

Economic and clinical advantages

• Delivers higher reimbursement and economic upside for hospitals and radiology providers, with up to AUD 1,500 per commercial scan.

• Clinical studies show improved surgical outcomes, with LVRS success rates rising from 46% to 76%.

• Rapid adoption by leading U.S. hospitals and imaging chains, including Stanford, Mayo, Cleveland Clinic, and SimonMed.